Czech Rep's Tamda Expects Higher Turnover
Tamda AS, the third-largest pharmaceutical distributor in the Czech Republic, expects its turnover to increase to 2 billion koruna ($76.4 million) this year and its net profit to significantly exceed its 1994 sales level of 1.5 million koruna, according to the CTR new agency's Business News.
Tamda, based in Ostrave in the northern Moravis region of the country, is owed 30 million koruna by customers, and is aiming to reduce its high stock levels. The company invested 23.5 million koruna in new technology last year, while this year's investment is expected to reach 25-30 million koruna.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze